COMT val158met is not associated with Aβ-amyloid and APOE ε4 related cognitive decline in cognitively normal older adults

Tenielle Porter; Samantha C. Burnham; Lidija Milicic; Greg Savage; Paul Maruff; Hamid R. Sohrabi; Madeline Peretti; Yen Ying Lim; Michael Weinborn; David Ames; Colin L. Masters; Ralph N. Martins; Stephanie Rainey-Smith; Christopher C. Rowe; Olivier Salvado; David Groth; Giuseppe Verdile; Victor L. Villemagne; Simon M. Laws

IBRO Reports (Jun 2019)

COMT val158met is not associated with Aβ-amyloid and APOE ε4 related cognitive decline in cognitively normal older adults

Tenielle Porter,
Samantha C. Burnham,
Lidija Milicic,
Greg Savage,
Paul Maruff,
Hamid R. Sohrabi,
Madeline Peretti,
Yen Ying Lim,
Michael Weinborn,
David Ames,
Colin L. Masters,
Ralph N. Martins,
Stephanie Rainey-Smith,
Christopher C. Rowe,
Olivier Salvado,
David Groth,
Giuseppe Verdile,
Victor L. Villemagne,
Simon M. Laws

Affiliations

Tenielle Porter: Collaborative Genomics Group, Centre of Excellence for Alzheimer’s Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup 6027, Western Australia, Australia; Cooperative Research Centre for Mental Health, Australia1
Samantha C. Burnham: CSIRO Health and Biosecurity, Parkville 3052, Victoria, Australia; Centre of Excellence for Alzheimer’s Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup 6027, Western Australia, Australia
Lidija Milicic: Collaborative Genomics Group, Centre of Excellence for Alzheimer’s Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup 6027, Western Australia, Australia; Cooperative Research Centre for Mental Health, Australia1
Greg Savage: ARC Centre of Excellence in Cognition and its Disorders, Department of Psychology, Macquarie University, North Ryde 2113, NSW, Australia
Paul Maruff: The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville 3052, Victoria, Australia; CogState Ltd., Melbourne 3000, Victoria, Australia
Hamid R. Sohrabi: Centre of Excellence for Alzheimer’s Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup 6027, Western Australia, Australia
Madeline Peretti: Collaborative Genomics Group, Centre of Excellence for Alzheimer’s Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup 6027, Western Australia, Australia; Cooperative Research Centre for Mental Health, Australia1
Yen Ying Lim: The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville 3052, Victoria, Australia
Michael Weinborn: Centre of Excellence for Alzheimer’s Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup 6027, Western Australia, Australia; School of Psychology, University of Western Australia, Crawley 6009, Western Australia, Australia
David Ames: Academic Unit for Psychiatry of Old Age, St. Vincent’s Health, The University of Melbourne, Kew 3101, Victoria, Australia; National Ageing Research Institute, Parkville 3052, Victoria, Australia
Colin L. Masters: The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville 3052, Victoria, Australia
Ralph N. Martins: Centre of Excellence for Alzheimer’s Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup 6027, Western Australia, Australia
Stephanie Rainey-Smith: Centre of Excellence for Alzheimer’s Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup 6027, Western Australia, Australia
Christopher C. Rowe: Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg 3084, Victoria, Australia; Department of Medicine, Austin Health, The University of Melbourne, Heidelberg 3084, Victoria, Australia
Olivier Salvado: CSIRO Health and Biosecurity/Australian e-Health Research Centre, Herston 4029, Queensland, Australia
David Groth: School of Pharmacy and Biomedical Sciences, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Bentley 6102, Western Australia, Australia
Giuseppe Verdile: Centre of Excellence for Alzheimer’s Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup 6027, Western Australia, Australia; School of Pharmacy and Biomedical Sciences, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Bentley 6102, Western Australia, Australia
Victor L. Villemagne: The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville 3052, Victoria, Australia; Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg 3084, Victoria, Australia; Department of Medicine, Austin Health, The University of Melbourne, Heidelberg 3084, Victoria, Australia
Simon M. Laws: Collaborative Genomics Group, Centre of Excellence for Alzheimer’s Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup 6027, Western Australia, Australia; Cooperative Research Centre for Mental Health, Australia1; School of Pharmacy and Biomedical Sciences, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Bentley 6102, Western Australia, Australia; Corresponding author at: Collaborative Genomics Group, School of Medical and Health Sciences, Edith Cowan University, 270 Joondalup Drive, Joondalup 6027, Western Australia, Australia.

Journal volume & issue: Vol. 6
pp. 147 – 152

Abstract

Read online

The non-synonymous single nucleotide polymorphism (SNP), Val158Met within the Catechol-O-methyltransferase (COMT) gene has been associated with altered levels of cognition and memory performance in cognitively normal adults. This study aimed to investigate the independent and interactional effects of COMT Val158Met on cognitive performance. In particular, it was hypothesised that COMT Val158Met would modify the effect of neocortical Aβ-amyloid (Aβ) accumulation and carriage of the apolipoprotein E (APOE) ε4 allele on cognition in preclinical Alzheimer’s disease (AD). In 598 cognitively normal older adults with known neocortical Aβ levels, linear mixed modelling revealed no significant independent or interactional associations between COMT Val158Met and cognitive decline. These findings do not support previous associations between COMT Val158Met and cognitive performance and suggest this variant does not influence Aβ-amyloid or APOE ε4 driven cognitive decline in a well characterised cohort of cognitively normal older adults. Keywords: Catechol-O-methyltransferase, COMT, Cognitive decline, Episodic memory, Aβ-amyloid

Published in IBRO Reports

ISSN: 2451-8301 (Online)
Publisher: Elsevier
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Neurosciences. Biological psychiatry. Neuropsychiatry
Website: https://www.journals.elsevier.com/ibro-reports/

About the journal